Celgene’s Revlimid Phase II Data Sufficient For Full Approval In MDS
FDA’s Oncologic Drugs Advisory Committee recommends full approval of Celgene’s Revlimid for myelodysplastic syndromes despite FDA concerns about trial design, dosing and toxicity.
FDA’s Oncologic Drugs Advisory Committee recommends full approval of Celgene’s Revlimid for myelodysplastic syndromes despite FDA concerns about trial design, dosing and toxicity.